Neurology and psychiatry are challenging areas for medical diagnosis and treatment. Psychiatric and neurological disorders are the subject of rapid scientific developments particularly regarding the role of centrally-active treatments.

Solvay psychiatric research has contributed substantially to the current knowledge of the role of serotonin in a wide variety of psychiatric disorders. The Solvay anti-depressant fluvoxamine was the first SSRI to reach the market (in 1983).

Parkinsons’s disease medication, DUODOPA® is Solvay’s first commercial contribution to patients suffering from the late stage of the malady.